We are monitoring the impact of COVID-19 on North America Gene Therapy Market Get in touch with us for detailed analysis Know More
Pulished Date July, 2021
ID: 11789
Share on
Share on

North America Gene Therapy Market Research Report - Segmented By Vector Type, Application and Country (The United States, Canada and Rest of North America) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast (2021 to 2026)

Pulished: July, 2021
ID: 11789
Pages: 100

North America Gene Therapy Market Size (2021 to 2026)

The size of the gene therapy market in the North American region is estimated to grow at a CAGR of 28.84% during the forecast period.

The expanding field of advanced therapies and gene delivery technologies has created an increasingly competitive dynamic in which a significant number of market players are participating in the commercialization of their gene therapy products. In addition, Gene Therapy developers are investing in Medicine & Agriculture industries as a viable strategy to enhance internal expertise and strengthen product lines. These factors are expected to drive the North American gene therapy market growth.

Increased funding of R&D activities related to gene therapy and increased awareness of gene therapy are the major growth factors of the gene therapy market. Additionally, increased government support, ethical acceptance of gene therapy for cancer treatment, and increased prevalence of cancer may drive the growth of the North American gene therapy market.

The United States Food and Drug Administration (FDA) has stated it expects to receive more than 200 applications of this therapy by the end of 2020. This shows that the growing number of research studies and innovations in this area would positively affect the gene therapy market's growth in the near future. In the U.S., nearly 220 companies currently operate in this market. On top of that, the Alliance for Regenerative Medicine said that in mid-2019, around 270 potential drug candidates were in clinical trials around the world.

Although the high prices of currently available therapies encourage the development of therapies, this limits accessibility and may lead to recalls in the market due to the lack of economic viability of the products. In addition, currently, Health officials are only prioritizing drugs associated with the coronavirus that make treatment easier. Therefore, there has been no increase in the application of possible drugs for gene therapy. These factors may hamper the growth of the market for years to come.

Impact of COVID-19 on the North American Gene Therapy Market:

Currently, the world is trying to mitigate the negative impact of the SARS-CoV-2 pandemic to restore the flow of income to the markets. As a result, the cell and gene therapy sector has been severely affected. As many universities have closed and halted all non-essential research and registration processes for clinical trials, ongoing R&D progress has been slow.

However, biopharmaceutical companies have undertaken various initiatives to gain a competitive advantage in the market. For example, companies adopt various go-to-market strategies, such as expanding biopharmaceutical facilities, collaborating with other key stakeholders, and developing with contract manufacturing organizations (CMOS).

This research report on the North American Gene Therapy Market has been segmented & sub-segmented into the following categories:

 By Vector Type:

  • Viral vector
    • Retroviruses
    • Lentiviruses
    • Adenoviruses
    • Adeno-associated Virus
    • Herpes Simplex Virus
    • Poxvirus
    • Vaccinia Virus
    • Others
  • Non-viral vector
    • Naked/Plasmid Vectors
    • Gene Gun
    • Electroporation
    • Lipofection
    • Others

By Application:

  • Oncological Disorders
  • Rare Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious disease
  • Other Diseases

By Country:

  • The U.S.
  • Canada
  • Rest of North America

Geographically, the U.S. gene therapy market is forecasted to account for most of the share in the North American market during the forecast period. Due to a strong regulatory framework to promote the development of cell therapy and the presence of a significant number of biopharmaceutical companies, several government agencies are investing in the region. This, in turn, stimulates the growth of the regional market. The presence of centers and institutes dedicated to R&D in gene therapy should continue to drive the United States of America market. Several companies in regions plan to receive FDA approvals focusing on the healthcare sector during the forecast period.

In 2019, the United States generated $ 2.16 billion in revenue in gene therapy. It was expected to dominate over the next few years, fueled by the increasing use of advanced gene therapies to treat rare diseases. Besides, the presence of favorable reimbursement policies and guidelines would also help drive the growth of the market here. Moreover, as this type of treatment is not legal in several developing countries, the industry giants are focusing on the United States to launch their products.

KEY MARKET PLAYERS:

A few of the promising companies operating in the North American gene therapy market profiled in this report are Biogen, Sarepta Therapeutics, Gilead Sciences, Inc., Amgen, Inc., Novartis AG, Orchard Therapeutics Plc, Spark Therapeutics, Inc., Molmed S.P.A., Anges, Inc., Bluebird Bio, Inc., Jazz Pharmaceuticals Plc, Dynavax Technologies, Human Stem Cells Institute, Sibiono Genetech Co., Ltd., Shanghai Sunway Biotech Co., Ltd., Uniqure N.V., Gensight Biologics S.A., Celgene Corporation, Cellectis, Sangamo Therapeutics, Mustang Bio, Applied Genetic Technologies Corporation and Poseida Therapeutics, Inc.

  1. INTRODUCTION
    1. Market Definition
    2. Study Deliverables
    3. Base Currency, Base Year, and Forecast Periods
    4. General Study Assumptions
  2. RESEARCH METHODOLOGY
    1. Introduction
    2. Research Phases
      1. Secondary Research
      2. Primary Research
      3. Econometric Modelling
      4. Expert Validation
    3. Analysis Design
    4. Study Timeline
  3. Report Overview
    1. Executive Summary
    2. Key Inferences
  4. Market Dynamics
    1. Impact Analysis
      1. Drivers
      2. Restraints
      3. Opportunities       
    2. Regulatory Environment
    3. Technology Timeline & Recent Trends
  5. Competitor Benchmarking Analysis
    1. Key Player Benchmarking                    
      1. Market share analysis      
      2. Products/Service
      3. Regional Presence               
    2. Mergers & Acquisition Landscape                     
    3. Joint Ventures & Collaborations
  6. MARKET SEGMENTATION
    1. By Vector Type
      1. Viral vector
        1. Retroviruses
        2. Lentiviruses
        3. Adenoviruses
        4. Adeno-associated Virus
        5. Herpes Simplex Virus
        6. Poxvirus
        7. Vaccinia Virus
        8. Others
      2. Non-viral vector
        1. Naked/Plasmid Vectors
        2. Gene Gun
        3. Electroporation
        4. Lipofection
        5. Others
      3. Y-o-Y Growth Analysis, By Vector Type
      4. Market Attractiveness Analysis, By Vector Type
      5. Market Share Analysis, By Vector Type
    2. By Application
      1. Oncological Disorders
      2. Rare Diseases
      3. Cardiovascular Diseases
      4. Neurological Disorders
      5. Infectious disease
      6. Other Diseases
      7. Y-o-Y Growth Analysis, By Application
      8. Market Attractiveness Analysis, By Application
      9. Market Share Analysis, By Application
  7. GEOGRAPHICAL ANALYSIS
    1. Introduction
      1. Regional Trends
      2. Impact Analysis
      3. Y-o-Y Growth Analysis
      4. Market Attractiveness Analysis
      5. Market Share Analysis
    2. North America
      1. Introduction
      2. The United States
      3. Canada
      4. Rest of North America
  8. STRATEGIC ANALYSIS
    1. PESTLE analysis
      1. Political
      2. Economic
      3. Social
      4. Technological
      5. Legal
      6. Environmental
    2. Porter’s Five analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Consumers
      3. The threat of New Entrants
      4. The Threat of Substitute Products and Services
      5. Competitive Rivalry within the Industry
  9. MARKET LEADERS' ANALYSIS
    1. Biogen
      1. Overview
      2. Products
      3. Financials (subjected to availability based on company type)
      4. Recent Developments
      5. SWOT analysis
      6. Analyst View
    2. Sarepta Therapeutics
    3. Gilead Sciences, Inc.
    4. Amgen, Inc.
    5. Novartis AG
    6. Orchard Therapeutics Plc
    7. Spark Therapeutics, Inc.
    8. Molmed S.P.A.
    9. Anges, Inc.
    10. Bluebird Bio, Inc.
    11. Jazz Pharmaceuticals Plc
    12. Dynavax Technologies
    13. Human Stem Cells Institute
    14. Sibiono Genetech Co., Ltd.
    15. Shanghai Sunway Biotech Co., Ltd.
    16. Uniqure N.V.
    17. Gensight Biologics S.A.
    18. Celgene Corporation
    19. Cellectis
    20. Sangamo Therapeutics
    21. Mustang Bio
    22. Applied Genetic Technologies Corporation
    23. Poseida Therapeutics, Inc.
  10. COMPETITIVE LANDSCAPE
    1. Market share analysis
    2. Merger and Acquisition Analysis
    3. Agreements, Collaborations and Joint Ventures
    4. New Product Launches
  11. MARKET OUTLOOK AND INVESTMENT OPPORTUNITIES
  12. APPENDIX
    1. List of Tables
    2. List of Figures
  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
  • Segment-level analysis in terms of vector type and application along with market size forecasts and estimations to detect key areas of industry growth in detail.
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development.
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment.
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies.
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions.
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market.
  1. North America Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  2. North America Viral vector Market, By Region, From 2021 to 2026 (USD Billion)
  3. North America Non-viral vector Market, By Region, From 2021 to 2026 (USD Billion)
  4. North America Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  5. North America Oncological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  6. North America Rare Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  7. North America Cardiovascular Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  8. North America Neurological Disorders Market, By Region, From 2021 to 2026 (USD Billion)
  9. North America Infectious disease Market, By Region, From 2021 to 2026 (USD Billion)
  10. North America Other Diseases Market, By Region, From 2021 to 2026 (USD Billion)
  11. United States Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  12. United States Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  13. Canada Gene Therapy Market, By Vector Type, From 2021 to 2026 (USD Billion)
  14. Canada Gene Therapy Market, By Application, From 2021 to 2026 (USD Billion)
  15. North America Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  16. North America Retroviruses Market, By Region, From 2021 to 2026 (USD Billion)
  17. North America Lentiviruses Market, By Region, From 2021 to 2026 (USD Billion)
  18. North America Adenoviruses Market, By Region, From 2021 to 2026 (USD Billion)
  19. North America Adeno-associated Virus Market, By Region, From 2021 to 2026 (USD Billion)
  20. North America Herpes Simplex Virus Market, By Region, From 2021 to 2026 (USD Billion)
  21. North America Poxvirus Market, By Region, From 2021 to 2026 (USD Billion)
  22. North America Vaccinia Virus Market, By Region, From 2021 to 2026 (USD Billion)
  23. United States Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  24. Canada Gene Therapy Market, By Viral vector, From 2021 to 2026 (USD Billion)
  25. North America Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  26. North America Naked/Plasmid Vectors Market, By Region, From 2021 to 2026 (USD Billion)
  27. North America Gene Gun Market, By Region, From 2021 to 2026 (USD Billion)
  28. North America Electroporation Market, By Region, From 2021 to 2026 (USD Billion)
  29. North America Lipofection Market, By Region, From 2021 to 2026 (USD Billion)
  30. North America Others Market, By Region, From 2021 to 2026 (USD Billion)
  31. United States Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)
  32. Canada Gene Therapy Market, By Non-viral vector, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample